Locations:
Search IconSearch
January 28, 2020/Cancer

Breaking Ground: Cleveland Clinic Abu Dhabi’s New Approach to Fighting Cancer

A central hub for patient care and research expands Cleveland Clinic's world-class care around the globe

Cleveland Clinic Abu Dhabi Cancer Center

As the third leading cause of death in Abu Dhabi, cancer affects millions of patients and families across the region. Cleveland Clinic Abu Dhabi has broken ground on a state-of-the-art oncology center, a significant step in the UAE’s fight against the disease. The center is designed to meet the specific needs of cancer patients and their treatments and will bring an integrated and transformative approach to diagnosing and treating cancer to the UAE.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“One of the main reasons patients travel abroad is to seek cancer treatment,” says Stephen Grobmyer, MD, Chair of Cleveland Clinic Abu Dhabi’s Oncology Institute. “Patients who come to us will now have access to comprehensive, personalized care at a single location, as well as an expanded range of treatments available.”

Dr. Grobmyer will lead the new 18,767 square meter purpose-built center modelled on Cleveland Clinic’s Taussig Cancer Center, which is ranked in the top 10 hospitals for cancer care nationally by U.S. News & World Report. He is an expert in the management of breast cancer and led the Cleveland Clinic Comprehensive Breast Cancer Program before coming to Cleveland Clinic Abu Dhabi.

“In the U.S., I saw how a change to centralized services positively impacted patients and their families, and we are thrilled to bring this model of care to the people of the UAE,” says Dr. Grobmyer.

A central hub for patient care and research

Designed with patients in mind, the nine-story facility will have dedicated clinical practice areas for advanced imaging, infusion, radiation and chemotherapy, as well as a connection to the main hospital’s surgical areas. The practice areas will have space for subspecialized nurses, social workers and patient support services.

The layout of each floor unites a range of complementary specialties, enhancing collaboration and enabling patients to receive most of their treatment in one area — a unique approach for patient care in the region. The center will have 24 exam rooms, 24 infusion rooms, two procedure rooms and an area devoted to specialty women’s services.

Advertisement

The building is designed to ensure the most comfortable flow for patients, provide an abundance of natural light and offer the optimal combination of clinical care with oncology patient support services and prayer rooms for patients.

In the future, it will also be a home for cancer research in the region, with a centralized hub for existing high-level treatment technology. “Our priority will be to answer cancer research questions that are specifically relevant to the people of the UAE and the regions that we serve. Areas of focus will be cancer screening and prevention, and investigating new technologies for cancer treatment.”

Expanding world-class care across the world

Cleveland Clinic Abu Dhabi’s current cancer services include positron emission tomography and computed tomography (PET-CT) for cancer diagnoses as well as advanced magnetic resonance imaging (MRI). Presently, advanced surgical procedures including robotics are performed for cancer patients with excellent results. Chemotherapy and other infusion treatments for cancer are also provided and supported by disease-specific tumor boards. When the center opens in 2022, services will expand to include radiation oncology, and disease-specific multidisciplinary teams will be fully enabled in the new oncology building to offer patients timely, state-of-the-art care in a supportive environment.

The new oncology center expands Cleveland Clinic’s efforts to bring world-class care to patients around the globe. “This really is a groundbreaking approach to cancer care that will not only serve the patients of the nation, but of the region and globe as well,” says Dr. Grobmyer. “This center will be the premier destination for cancer care in the Gulf region.”

Advertisement

Related Articles

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

Ad